-+ 0.00%
-+ 0.00%
-+ 0.00%

Telix Pharma Collaborates With Varian To Develop Clinical Applications That Combine Telix's Theranostic Products And External Beam Radiation Therapy

Benzinga·12/10/2025 12:04:50
Listen to the news

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology, to develop novel clinical applications that combine Telix's theranostic products and external beam radiation therapy (EBRT).

EBRT is a widely used and validated treatment suitable for most solid malignant tumors. This treatment is typically delivered by radiation oncologists who play a central role in managing cancer across multiple stages of the patient journey. The role of EBRT and radiation oncology in treating cancer could potentially be enhanced by integrating with therapeutic radiopharmaceuticals and precision diagnostics. Working with Varian, a key player in EBRT, Telix will explore how theranostics can be used more effectively by radiation oncologists to enhance patient selection and deliver targeted treatment.